On April 7, 2022 CytoImmune Therapeutics, a clinical-stage immunotherapy company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, reported that Christina Coughlin, M.D., Ph.D., chief executive officer, will participate in the following April investor conferences (Press release, CytoImmune Therapeutics, APR 7, 2022, View Source [SID1234611613]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Locust Walk Stem Cell Tx Conference in Partnership with Harvard Stem Cell Institute (formal presentation) on Monday, April 11, 2022, at 11:00 a.m. ET;
Needham 21st Annual Virtual Healthcare Conference’s "NK Therapeutics Panel" on Thursday, April 14, 2022, at 11:45 a.m. ET; and,
Chardan Annual Genetic Medicines & Cell Therapy Manufacturing Summit (fireside chat) on Monday, April 25, 2022, at 9:00 a.m. ET.